Veloxis completes enrolment in LCP-Tacro 3002 phase III study in kidney transplant pharmabiz.com Tacrolimus is a leading immunosuppression drug used for the prevention of transplant allograft rejection after organ transplantation. LCP-Tacro is being developed as a once-daily tablet version of tacrolimus, with improved bioavailability, ... |
